PET/CT Clinical Trial
Official title:
Negative Oral Contrast Agents Utilization in PET/CT Studies
To compare the performance of different negative oral contrast agents in bowel distension in patient referred for PET/CT studies for various causes aiming for identification of ideal oral contrast agent(OCA).
Evaluation of gastrointestinal pathology depends on adequate bowel distention, which
optimizes resolution of the bowel wall and contents. Traditionally, high-attenuation oral
Contrast material in the form of iodine solutions or barium suspensions has been used to
obtain bowel distension in MDCT examinations
Traditional high-contrast oral agents like iodine solutions, and barium suspensions which due
to overcorrection problems in PET-CT interpretation lowers the accuracy of diagnosis.
Negative oral contrast agents like water, air, fat containing agents used with 12.5% corn oil
and polyethylene glycol has been used in radiological studies. Milk with 4% fat content has
also been tested out in radiological studies and found to be effective. As it is more easily
available, palatable, and acceptable especially, by children it needed to be tested in the
visualization of the GIT in the PET-CT studies compared to other negative contrast agents.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT05030597 -
Exploring the Application Value of PET Molecular Imaging Targeting FAP in Oral Squamous Cell Carcinoma
|
N/A | |
| Recruiting |
NCT05496920 -
Assessing Ultra-low Dose PET/CT and CT-less PET Using a Long Axial Field-of-view PET/CT System
|
N/A | |
| Recruiting |
NCT04586465 -
Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC
|
Phase 2 | |
| Recruiting |
NCT04553601 -
Molecular Imaging Visualization of Tumor Heterogeneity in Non-small Cell Lung Cancer
|
N/A | |
| Recruiting |
NCT05707078 -
PET/CT Follow up for Head and Neck Squamous Cell Carcinoma
|
N/A | |
| Recruiting |
NCT06320223 -
PROMISE PET Registry on PSMA-PET and Outcome in Prostate Cancer
|
||
| Recruiting |
NCT05255926 -
CXCR4-targeted PET/CT Imaging in Hematological Malignancies
|
N/A | |
| Recruiting |
NCT05955677 -
Head-to-head Comparison of [68Ga]Ga-PSMA-D5 With [68Ga]Ga-PSMA-11 PET/CT in PCa Diagnosis, Recurrence, and Metastasis
|
Early Phase 1 | |
| Recruiting |
NCT04588064 -
18F-FDG and 68Ga-FAPI PET/CT in Lung Adenocarcinoma
|
N/A | |
| Active, not recruiting |
NCT04519255 -
Study for Quantitative Analysis of the Recovered COVID-19 Patients by 18F-FDG-PET/CT
|
||
| Recruiting |
NCT05835570 -
Integrin αvβ6-targeted PET in Malignant Tumors
|
||
| Active, not recruiting |
NCT05819905 -
Radiomics for prEdiction of lunG cAncer biologY
|
||
| Recruiting |
NCT05034146 -
68Ga-FAPI PET/CT in Malignant Tumors
|
N/A | |
| Recruiting |
NCT05156515 -
PD-L1 Targeting Nanobody Probe for PET Imaging of Solid Tumor
|
N/A | |
| Terminated |
NCT03423407 -
Evaluation of Attenuation Correction Accuracy in Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI)
|
||
| Completed |
NCT05134064 -
68Ga-PSMA PET/CT Imaging in Assessment of Prostate Cancer
|
||
| Recruiting |
NCT03756077 -
A Study of the Value of Hybrid PET/MR and PET/CT in Prostate Cancer
|
||
| Not yet recruiting |
NCT06353061 -
Chemoradiotherapy With or Without Metformin in Locally Advanced Cervical Cancer
|
Phase 2 |